Furthermore, Dr Reddy's has also hinted that it is vertically integrated and fully prepared to capture the GLP-1 ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Qiagen NV added to its growing roster of panels cleared by the U.S. FDA in 2024 with the agency’s nod for its Qiastat-Dx Meningitis/Encephalitis assay. The clearance validates Qiagen’s strategy of ...

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) set up its second overseas regulatory office in Washington, four ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed.

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS), according to ...